The VISA/GISA problem: Therapeutic implications

Clinical Microbiology and Infection

Volumn 7, Issue SUPPL. 4, 2001, Pages 8-15

  Linares J ^a  

^a HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

Author keywords

GISA; Resistance; Staphylococcus aureus; Treatment; Vancomycin; VISA

Indexed keywords

AGAR; AMIKACIN; AMPHOTERICIN B; AMPICILLIN; BETA LACTAM ANTIBIOTIC; CEFPIROME; CEFTRIAXONE; CHLORAMPHENICOL; CIPROFLOXACIN; COTRIMOXAZOLE; DALFOPRISTIN PLUS QUINUPRISTIN; DAPTOMYCIN; DOXYCYCLINE; ERYTHROMYCIN; GENTAMICIN; HABEKACIN; LINEZOLID; METICILLIN; METRONIDAZOLE; NAFCILLIN; PENICILLIN G; POLYPEPTIDE ANTIBIOTIC AGENT; PRISTINAMYCIN; RIFAMPICIN; SULBACTAM; TEICOPLANIN; TETRACYCLINE; TOBRAMYCIN; UNINDEXED DRUG; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL GROWTH; BACTERIAL STRAIN; BACTERIUM ISOLATE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG POTENTIATION; EUROPE; FRANCE; HONG KONG; HUMAN; IN VITRO STUDY; IN VIVO STUDY; JAPAN; KOREA; LONG TERM CARE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRACTICE GUIDELINE; PRIORITY JOURNAL; STAPHYLOCOCCUS INFECTION; THAILAND; TREATMENT FAILURE; UNITED STATES;

BACTERIA (MICROORGANISMS); METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS; STAPHYLOCOCCUS AUREUS;

EID: 0035746934     PISSN: 1198743X     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1469-0691.2001.00054.x     Document Type: Article

References (81)

1. Staphylococcus aureus (including toxic shock syndrome)
2. 'Celbenin'-resistant staphylococci
3. Methicillin-resistant Staphylococcus aureus
4. Antibiotics for treatment of infections caused by MRSA and elimination of MRSA carriage. What are the choices?
5. Methicillin-resistant Staphylococcus aureus in US hospitals, 1975-91
6. Methicillin resistance in Europe
7. Spread and maintenance of a dominant methicillin-resistant Staphylococcus aureus (MRSA) clone during an outbreak of MRSA disease in spanish hospital
8. Emergence of vancomycin resistance in coagulase-negative staphylococci
9. Emergence of teicoplanin resistance during therapy of Staphylococcus aureus endocarditis
10. Failure of teicoplanin therapy in two neutropenic patients with staphylococcal septicemia who recovered after administration of vancomycin
11. Vancomycin-resistant Staphylococcus aureus: Apocalypse now?
12. Intermediate vancomycin resistance in Staphylococcus aureus: A major threat or a minor inconvenience?
13. Glycopeptide-intermediate Staphylococcus aureus rediscovery of an old problem?
14. Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility
15. Dissemination in Japanese hospitals of strains of Staphylococcus aureus heterogeneously resistant to vancomycin
16. Staphylococcus aureus with reduced susceptibility to vancomycin - United States 1997
17. Update: Staphylococcus aureus with reduced susceptibility to vancomycin - United States 1997
18. Staphylococcus aureus with reduced susceptibility to vancomycin - Japan States 1997
19. Staphylococcus aureus with reduced susceptibility to vancomycin - Illinois, 1999
20. Emergence of vancomycin resistance in Staphylococcus aureus
21. The development of vancomycin resistance in a patient with methicillin-resistant Staphylococcus aureus infection
22. Vancomycin-intermediate and resistant Staphylococcus aureus: What the infectious disease specialist needs to know
23. First clinical isolate of vancomycin-intermediate Staphylococcus aureus in a French hospital
24. Vancomycin resistant staphylococcus reported in Hong Kong
25. Vancomycin intermediate Staphylococcus aureus in Korea
26. Teicoplanin-resistant Staphylococcus aureus expresses a novel membrane protein and increases expression of penicillin-binding protein 2 complex
27. Characterization of Staphylococcus aureus isolates with decreased susceptibility to vancomycin and teicoplanin: Isolation and purification of a constitutively produced protein associated with decreased susceptibility
28. A highly vancomycin-resistant laboratory mutant of Staphylococcus aureus
29. Vancomycin resistance in staphylococci
30. The emergence of Staphylococcus aureus with reduced susceptibility to vancomycin in Japan
31. Reversion of glycopeptide resistance phenotype in Staphylococcus aureus clinical isolates
32. Activated cell-wall syntesis is associated with vancomycin resistance in methicillin-resistant Staphylococcus aureus strains Mu3 and Mu50
33. Inhibition of cell wall turnover and autolysis by vancomycin in a highly vancomycin-resistant mutant of Staphylococcus aureus
34. Suppression of beta-lactam antibiotic resistance in a methicillin-resistant Staphylococcus aureus through synergic action of early cell wall inhibitors and some other antibiotic
35. Suppression of glycopeptide resistance in a highly teicoplanin resistant mutant Staphylococcus aureus by transposon inactivation of genes involved in cell wall syntesis
36. Inactivated pbp4 in highly glycopeptide-resistant laboratory mutants of Staphylococcus aureus
37. Inactivation of the methicillin resistance gene mecA in vancomycin-resistant Staphylococcus aureus
38. Increase in glutamine-non-amidated muropeptides in the peptidoglycan of vancomycin-resistance Staphylococcus aureus strain Mu50
39. Co-transfer of vancomycin and other resistance genes from Enterococcus faecalis NCTC 12201 to Staphylococcus aureus
40. Some laboratory and clinical experience with a new antibiotic, vancomycin
41. Recommendations from MENSURA for selection of antimicrobial agents for susceptibility testing and criteria for the interpretation of antibiograms
42. Communiqué
43. Revised guidelines for the control of methicillin-resistant Staphylococcus aureus infection in hospitals
44. Antimicrobial susceptibility testing in Sweden
45. VRSA, VISA and GISA. the dilemma behind the name game
46. Vancomycin in surgical infections due to methicillin-resistant Staphylococcus aureus with heterogeneous resistance to vancomycin
47. Methicillin-resistant (MR) Staphylococcus aureus (SA) with reduced susceptibilities to glycopeptides in a Spanish hospital
48. Decreased teicoplanin susceptibility of methicillin-resistant strains of Staphylococcus aureus
49. Presence of Staphylococcus aureus with reduced susceptibility to vancomycin in Germany
50. Reduced susceptibility to teicoplanin in a methicillin-resistant strain of Staphylococcus aureus
51. Emergence of heterogeneous intermediate vancomycin resistance in Staphylococcus aureus isolates in the Dusseldorf area
52. Outbreak of methicillin-resistant Staphylococcus aureus with reduced susceptibility to glycopeptides in a Parisian hospital
53. Infections and colonizations due to methicillin-resistant Staphylococcus aureus with decreased-susceptibility to glycopeptides (GISA) in a medical intensive care unit (ICU)
54. Reduced susceptibility to vancomycin of nosocomial isolates of methicillin-resistant Staphylococcus aureus
55. Incidence of Staphylococcus aureus with reduced susceptibility to glycopeptides in two French hospitals
56. Heterogeneous vancomycin resistance in methicillin-resistant Staphylococcus aureus strains isolated in a large Italian hospital
57. First report of methicillin-resistant Staphylococcus aureus with reduced susceptibility to vancomycin in Thailand
58. Bacteremia caused by staphylococci with inducible vancomycin heteroresistance
59. Characterization of staphylococci with reduced susceptibilities to vancomycin and other glycopeptides
60. Expression and detection of hetero-vancomycin resistance in Staphylococcus aureus
61. Glycopeptide-intermediate Staphylococcus aureus evaluation of a novel screening method and results of a survey
62. Micro-method conditions are optimal for detecction of low level glycopeptide resistance in Staphylococci
63. Stable classes of phenotpic expression in methicillin-resistant clinical isolates of staphylococci
64. Emergence of methicillin-resistant Staphylococcus aureus with intermediate glycopeptide resistance. Clinical significance and treatment options
65. Staphylococcus aureus with reduced susceptibility to vancomycin isolated from a patient with fatal bacteremia
66. Emergence of methicillin resistant Staphylococcus aureus (MTRSA) with decreases susceptibility to vancomycin in a Belgian Hospital
67. Vancomycin resistant Staphylococcus aureus
68. Retrospective screening for heterogeneous vancomycin resistance in diverse Staphylococcus aureus clones disseminated in French hospitals
69. The specter of glycopeptide resistance: Current trends and future considerations
70. Vancomycin for Staphylococcus aureus endocarditis in intravenous drug users
71. Slow reponse to vancomycin plus rifampin in methicillin-resistant Staphylococcus aureus endocarditis
72. Interactions between methicillin and vancomycin in methicillin-resistant Staphylococcus aureus strains displaying phenotypes of vancomycin susceptibility
73. Combinations of vancomycin and beta-lactams are synergistic against staphylococci with reduced susceptibilities to vancomycin
74. Treatment of experimental staphylococcal endocarditis due to a strain with reduced susceptibility in vitro to vancomycin: Efficacy of ampicillin-sulbactam
75. Current and future management of infections due to methicillin-resistant staphylococci infections: The role of quinupristin/dalfopristin
76. Treatment of experimental endocarditis due to erythromycin-susceptible or -resistant Staphylococcus aureus with RP59500
77. Efficacy os Synercid (SYN) and/or cefpirome (CP) in the treatment (Rx) of experimental endocarditis (EE) due to glycopepetide intermediate Staphylococcus aureus (GISA)
78. In vitro activities of daptomycin, arbekacin, vancomycin, and gentamicin alone and/or combination against glycopeptide-intermediate resistant Staphylococcus aureus in an infection model
79. Interim guidelines for prevention and control of staphylococcal infection associated with reduced susceptibility to vancomycin
80. Vancomycin-resistant of Staphylococcus aureus infection control considerations